RNA transfection is an essential tool in molecular biology, enabling researchers to precisely manipulate gene expression, develop RNA-based therapeutics, and advance functional genomics. Altogen Biosystems specializes in high-efficiency RNA transfection solutions designed for cancer research applications. Our advanced transfection reagents and kits enable precise modulation of gene expression in cancer cell lines, facilitating studies on oncogenes, tumor suppressors, and RNA-based therapeutics. Browse Our Products.
Cutting-Edge Transfection Technologies
Altogen Biosystems remains at the forefront of RNA transfection technology by providing a diverse range of advanced transfection solutions tailored to meet the needs of modern research. Our innovative transfection technologies deliver superior efficiency, precision, and reproducibility across various experimental applications.
Our lipid-based transfection technology offers an optimized approach for in vivo lipid nanoparticle delivery, ensuring high-efficiency transfection of siRNA, mRNA, and miRNA. Designed to facilitate gene modulation with minimal cytotoxicity, this method enables efficient delivery even in challenging cancer cell lines that typically exhibit resistance to traditional transfection techniques. With an emphasis on safety and reliability, lipid-based transfection has become the preferred method for researchers aiming for precise gene expression and gene silencing.
Electroporation
For researchers working with difficult-to-transfect cells, electroporation provides a powerful alternative to chemical transfection. This high-voltage technique enhances transfection success by enabling direct cytoplasmic delivery of RNA molecules. Electroporation is particularly advantageous for primary cells, stem cells, and immune cells that may be resistant to conventional lipid-based transfection. By offering precise control over voltage and pulse duration, our electroporation solutions provide enhanced RNA uptake and improved experimental reproducibility.
RNA transfection plays a critical role in CRISPR-based gene editing, facilitating the delivery of guide RNA (gRNA) required for highly specific gene modifications. Our transfection reagents ensure efficient, on-target gene editing with minimal off-target effects, making them ideal for functional genomics studies, gene knockout experiments, and the development of targeted cancer therapies. By accelerating the precision of gene editing, Altogen Biosystems empowers researchers to conduct groundbreaking research in genome engineering.
Optimized Solutions for Every RNA Type
Altogen Biosystems’ cutting-edge transfection reagents support the efficient delivery of various RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), ribozymes, viral RNA, RNA oligonucleotides, and in vitro transcribed RNA. Each RNA type presents distinct structural and functional attributes, requiring specialized transfection conditions for optimal performance. Our proprietary formulations ensure maximum RNA stability, enhanced transfection efficiency, and superior gene expression outcomes.
Messenger RNA is commonly used for gene expression studies, vaccine development, and therapeutic applications, with our reagents ensuring high mRNA stability and translation efficiency. Our siRNA transfection reagents provide precise and effective gene silencing, minimizing off-target effects while ensuring maximum knockdown efficiency. Functional studies utilizing ribozymes and RNA oligonucleotides benefit from our reagents’ superior delivery and minimal cytotoxicity. In vitro transcribed RNA and viral RNA transfection solutions are engineered for gene therapy research, offering a safe and efficient alternative to viral vector-based gene delivery. By providing tailored solutions for each RNA type and experimental need, Altogen Biosystems ensures optimal transfection performance for every research application.
Enhanced RNA Stability and Transfection Efficiency
Achieving reliable and reproducible results requires the use of high-purity, chemically modified RNA designed to enhance stability, minimize immunogenicity, and ensure consistent transfection outcomes. Our advanced formulations optimize transfection efficiency while maintaining high cell viability, making them ideal for a broad range of research applications. By reducing cellular stress and improving RNA uptake, Altogen Biosystems enables more accurate and reproducible gene expression studies, RNA-based therapeutics development, and functional genomics research. Our reagents provide exceptional RNA stability, allowing researchers to conduct long-term studies without compromising transfection efficiency.
RNA Transfection into Cultured Cells (In Vitro)
Since the introduction of RNA transfection, scientists have continued to refine methods for delivering RNA into cultured cells. One of the most well-documented experiments involved the transfection of Photinus pyralis (eastern firefly) luciferase mRNA into NIH 3T3 mouse fibroblast cells cultured in vitro. Following transfection, cells exhibited luciferase activity, demonstrating the successful translation of transfected mRNA. Further studies revealed that untranslated beta-globin sequences enhanced luciferase protein production, indicating that structural elements of mRNA influence transfection efficiency.
The cationic liposome transfection method proved to be more efficient and less toxic than the DEAE-dextran RNA transfection method, offering higher transfection rates across diverse cell types. This approach remains one of the most widely used methods for RNA transfection into mammalian cells, supporting a broad range of gene expression, protein production, and therapeutic research applications.
Transfection of Mononuclear Cells of Human Peripheral Blood with mRNA
In immunotherapy and vaccine research, the ability to efficiently transfect mononuclear cells from human peripheral blood is crucial for stimulating antigen-specific cytotoxic T lymphocytes and enhancing cell-mediated immunity. Scientists have successfully transfected mononuclear cells (such as monocytes and dendritic cells) with mRNA, demonstrating their ability to activate memory T cells in vitro. This research underscores the potential of mRNA-based vaccines to induce robust immune responses, paving the way for next-generation immunotherapies.
By transfecting peripheral blood mononuclear cells (PBMCs) with mRNA, researchers have identified an effective and reproducible method for evaluating vaccine efficacy and immune response. This technique eliminates the need for monocyte-derived dendritic cells, offering a streamlined approach to mRNA-based vaccine development. Altogen Biosystems’ transfection reagents provide optimal delivery efficiency, ensuring robust antigen presentation and immune activation in experimental and clinical studies.
For researchers seeking industry-leading RNA transfection efficiency, Altogen Biosystems offers the most advanced and reliable transfection reagents available today. Our products are meticulously engineered to enhance RNA stability, optimize transfection conditions, and maximize gene expression or silencing, ensuring that every experiment leads to groundbreaking discoveries. With our industry-leading expertise, superior reagent formulations, and commitment to scientific advancement, we provide researchers with the tools they need to revolutionize their RNA transfection studies.
With a commitment to excellence in transfection science, Altogen Biosystems is the trusted partner for academic institutions, biotechnology companies, and pharmaceutical researchers worldwide. Our expertise in gene silencing, RNA delivery, and genome engineering ensures that every experiment benefits from the highest level of precision and efficiency.